Cartesian Reports Durable Descartes-08 Retreatment Data in MG
FREDERICK, Md. — September 29, 2026 Cartesian Therapeutics announced additional retreatment data from its Phase 2 program evaluating Descartes-08,...
Givinostat
Advertisement
Cognition Therapeutics Schedules FDA Type C Meeting for Zervimesine
PURCHASE, N.Y. — September 29, 2026 Cognition Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) Division...
JCR Gains Japan Orphan Drug Designation for Givinostat
HYOGO, Japan — September 28, 2026 JCR Pharmaceuticals Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare...
Italfarmaco Secures Managed Entry Agreement for Duvyzat in Georgia
MILAN, Italy, July 31, 2026 talfarmaco S.p.A. announced a managed entry agreement with the Georgian Ministry of Health to...
Italfarmaco–JCR Givinostat Deal Expands Rare Disease Pharma in Japan
MILAN, Italy & HYOGO, Japan | December 24, 2025 — Italfarmaco and JCR Pharmaceuticals have announced a landmark commercialisation...
Advertisement
